1_DrugVSCTL_Gene_differential_expression.xlsx

To glean insight into the genetic variation involved in acquired cisplatin resistance, we established an in vivo model of cisplatin-resistant cancer by administering a serial dose of
cisplatin to mice bearing KB-3-1 human carcinoma cells. Through a whole transcriptome analysis using RNAseq, we set to identify significantly changed genes in tumors that acquired cisplatin resistance compared to treatment-naïve tumors.